Clementia Pharmaceuticals (Clementia Pharmaceuticals) DeferredTaxAndRevenue : $0.00 Mil (As of Dec. 2018)

View and export this data going back to 2017. Start your Free Trial

What is Clementia Pharmaceuticals DeferredTaxAndRevenue?

Deferred Tax And Revenue represents the current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Clementia Pharmaceuticals's current deferred tax and revenue for the quarter that ended in Dec. 2018 was $0.00 Mil.

Clementia Pharmaceuticals DeferredTaxAndRevenue Historical Data

The historical data trend for Clementia Pharmaceuticals's DeferredTaxAndRevenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clementia Pharmaceuticals DeferredTaxAndRevenue Chart

Clementia Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

DeferredTaxAndRevenue

Clementia Pharmaceuticals Quarterly Data
	Dec14	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18
DeferredTaxAndRevenue	Get a 7-Day Free Trial									-	-	-	-	-

Clementia Pharmaceuticals DeferredTaxAndRevenue Related Terms

Thank you for viewing the detailed overview of Clementia Pharmaceuticals's DeferredTaxAndRevenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Clementia Pharmaceuticals (Clementia Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clementia Pharmaceuticals Inc (NAS:CMTA) » Definitions » DeferredTaxAndRevenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

4150 St Catherine Street West, Suite 550, Montreal, QC, CAN, H3Z 2Y5

Website

http://www.clementiapharma.com

Clementia Pharmaceuticals Inc is a clinical stage biopharmaceutical company. It is developing disease-modifying treatments for patients suffering from debilitating bone and other diseases with high unmet medical need. The company's lead product candidate, palovarotene, is an oral small molecule that has shown potent activity in preventing abnormal new bone formation as well as fibrosis in a variety of tissues. Clementia is developing palovarotene for the treatment of Fibrodysplasia Ossificans Progressiva (FOP) and Multiple Osteochondroma (MO). It believes that if approved in FOP or MO, palovarotene could become the standard of care in either or both of these indications.